Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 1 to 25 of 1146 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
890 decreased gene expression (GO:0010467) zinc finger protein GLI2 (PR:000008027) 2040: Decrease, GLI1/2 target gene expression
886 decreased protein import into nucleus, translocation (GO:0000060) zinc finger protein GLI2 (PR:000008027) 2028: Decrease, GLI1/2 translocation to nucleus
884 decreased protein import into nucleus, translocation (GO:0000060) zinc finger protein GLI1 (human) (PR:P08151) None
889 decreased gene expression (GO:0010467) zinc finger protein GLI1 (PR:000008026) 2040: Decrease, GLI1/2 target gene expression
885 decreased protein import into nucleus, translocation (GO:0000060) zinc finger protein GLI1 (PR:000008026) 2028: Decrease, GLI1/2 translocation to nucleus
194 increased covalent binding (MI:0195) xenobiotic (CHEBI:35703) 75: N/A, Covalent binding to protein, possibly lysine residue
148 increased hemoglobin biosynthetic process (GO:0042541) xenobiotic (CHEBI:35703) 118: Formation, Formation of hemoglobin adducts
683 abnormal signaling (GO:0023052) Wnt signalosome (GO:1990909) 1294: Inhibition, Wnt pathway
97 abnormal Wnt signaling pathway (GO:0016055) Wnt signalosome (GO:1990909) 310: Alteration, Wnt pathway
717 decreased hypoxia (MP:0005039) von Hippel-Lindau disease tumor suppressor (PR:000017294) 1394: Induction, persistent proliferation/sustained proliferation
718 decreased hypoxia-inducible factor-1alpha signaling pathway (GO:0097411) von Hippel-Lindau disease tumor suppressor (PR:000017294) None
986 functional change sodium channel activity (GO:0005272) voltage-gated sodium channel complex (GO:0001518) 1977: Disruption of sodium channel gating kinetics
776 decreased protein secretion (GO:0009306) vitellogenins (MESH:D014819) 285: Reduction, Vitellogenin synthesis in liver
111 decreased receptor-mediated endocytosis (GO:0006898) vitellogenins (MESH:D014819) 309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
139 increased gene expression (GO:0010467) vitellogenins (MESH:D014819)
138 increased vitellogenins (MESH:D014819)
110 decreased vitellogenins (MESH:D014819) 221: Reduction, Plasma vitellogenin concentrations
108 decreased gene expression (GO:0010467) vitellogenins (MESH:D014819) 285: Reduction, Vitellogenin synthesis in liver
593 decreased catalytic activity (GO:0003824) Vitamin K Epoxide Reductases (MESH:D064417) 1134: Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone
591 abnormal vitamin K metabolic process (GO:0042373) vitamin K (CHEBI:28384) 1134: Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone
756 increased viral RNA genome replication (GO:0039694) viral RNA-directed RNA polymerase complex (GO:0031381) 1847: Increased SARS-CoV-2 production
757 increased positive stranded viral RNA replication (GO:0039690) viral RNA-directed RNA polymerase complex (GO:0031381) 1847: Increased SARS-CoV-2 production
948 occurrence protein import into nucleus (GO:0006606) viral RNA-directed RNA polymerase complex (GO:0031381) 2192: Influenza A Virus production increased
909 occurrence viral entry into host cell (GO:0046718) viral protein (PR:000036197) 1738: SARS-CoV-2 cell entry
577 increased Viral load (MESH:D019562) 1109: Increased, Deformed Wing Virus levels